Treace Medical Faces Scrutiny Amid Stock Plunge

Investigation Launched Over Potential Securities Violations

The Law Offices of Howard G. Smith have initiated an investigation on behalf of Treace Medical Concepts, Inc. (“Treace” or the “Company”) TMCI. The focus is on whether the Company may have violated federal securities laws.

Financial Update Reveals Significant Adjustments

On May 7, 2024, Treace disclosed its first quarter financial results for 2024 and made a notable revision to its full year guidance, reducing it by approximately $20 million. This adjustment was attributed to “increased use of MIS Osteotomy solutions and more competition from knockoffs of [the Company’s] Lapiplasty products.”

Stock Value Takes a Sharp Hit

Following the announcement, Treace’s stock plummeted by $6.95, or 62.5%, closing at $4.17 per share on May 8, 2024. This decline significantly impacted investors who may have suffered losses.

Investor Help and Contact Information

Investors who purchased Treace securities, possess relevant information, or have questions about these developments are encouraged to reach out to Howard G. Smith, Esquire, at the Law Offices of Howard G. Smith. You can contact them at 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by calling (215) 638-4847, or by emailing [email protected]. More information is also available on their website at www.howardsmithlaw.com.

Note: This press release may be considered Attorney Advertising in certain jurisdictions under applicable law and ethical rules.